

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



AMMECR1L (h): 293T Lysate: sc-117438



The Power to Question

BACKGROUND

AMMECR1 (Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis chromosomal region gene 1), also known as AMME syndrome candidate gene 1 protein, is a 333 amino acid protein that contains one AMMECR1 domain. Encoded by a gene that maps to human chromosome Xq22.3, AMMECR1 is widely conserved, from *Caenorhabditis elegans* and yeast to microorganisms, with exon 2 encoding an evolutionarily conserved, six amino acid domain. Containing a glycine-rich N terminus, the AMMECR1 protein exhibits putative nuclear localization and a substantial level of instability, suggesting it plays a role in regulation. Additionally, numerous potential phosphorylation sites imply that AMMECR1 is subject to stringent regulation. AMMECR1 defects are linked to Alport syndrome, an X-linked contiguous gene deletion syndrome characterized by glomerulonephritis, deafness, mental retardation, midface hypoplasia and elliptocytosis.

REFERENCES

- 1. Piccini, M., et al. 1998. FACL4, a new gene encoding long-chain acyl-CoA synthetase 4, is deleted in a family with Alport syndrome, elliptocytosis, and mental retardation. Genomics 47: 350-358.
- Jonsson, J.J., et al. 1998. Alport syndrome, mental retardation, midface hypoplasia, and elliptocytosis: a new X linked contiguous gene deletion syndrome? J. Med. Genet. 35: 273-278.
- Vitelli, F., et al. 1999. Identification and characterization of a highly conserved protein absent in the Alport syndrome (A), mental retardation (M), midface hypoplasia (M), and elliptocytosis (E) contiguous gene deletion syndrome (AMME). Genomics 55: 335-340.
- Vitelli, F., et al. 2000. Identification and characterization of mouse orthologs of the AMMECR1 and FACL4 genes deleted in AMME syndrome: orthology of Xq22.3 and MmuXF1-F3. Cytogenet. Cell Genet. 88: 259-263.
- Kashtan, C.E. 2000. Alport syndromes: phenotypic heterogeneity of progressive hereditary nephritis. Pediatr. Nephrol. 14: 502-512.
- Ferrante, M.I., et al. 2001. IL1RAPL2 maps to Xq22 and is specifically expressed in the central nervous system. Gene 275: 217-221.
- Meloni, I., et al. 2002. Alport syndrome and mental retardation: clinical and genetic dissection of the contiguous gene deletion syndrome in Xq22.3 (ATS-MR). J. Med. Genet. 39: 359-365.
- 8. Tajika, Y., et al. 2005. Crystal structure of PH0010 from *Pyrococcus horikoshii*, which is highly homologous to human AMMECR 1C-terminal region. Proteins 58: 501-503.
- Hertz, J.M. 2009. Alport syndrome. Molecular genetic aspects. Dan. Med. Bull. 56: 105-152.

CHROMOSOMAL LOCATION

Genetic locus: AMMECR1L (human) mapping to 2q14.3.

PRODUCT

AMMECR1L (h): 293T Lysate represents a lysate of human AMMECR1L transfected 293T cells and is provided as 100 μ g protein in 200 μ l SDS-PAGE buffer.

APPLICATIONS

AMMECR1L (h): 293T Lysate is suitable as a Western Blotting positive control for human reactive AMMECR1L antibodies. Recommended use: 10-20 μ l per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com